Justus G. Garweg

Bern, BE, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 123 publications

Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report.

Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report.

Journal: Ophthalmology and therapy

Published: May 04, 2026

Practical Challenges for the Implementation of AI-Based Image Analysis in Ophthalmology Research: Insights and Recommendations from a Swiss Multicentric Study.

Practical Challenges for the Implementation of AI-Based Image Analysis in Ophthalmology Research: Insights and Recommendations from a Swiss Multicentric Study.

Journal: Klinische Monatsblatter fur Augenheilkunde

Published: April 20, 2026

Longitudinal Changes in Inner Retinal Layers in Treatment-Naïve Neovascular AMD During Intravitreal Anti-VEGF Therapy.

Longitudinal Changes in Inner Retinal Layers in Treatment-Naïve Neovascular AMD During Intravitreal Anti-VEGF Therapy.

Journal: Ophthalmology. Retina

Published: March 12, 2026

Correction: One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Correction: One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Journal: Ophthalmology and therapy

Published: February 28, 2026

Effect of key baseline disease characteristics on aflibercept 8 mg dosing interval extension: A post hoc 96-week analysis of PULSAR.

Effect of key baseline disease characteristics on aflibercept 8 mg dosing interval extension: A post hoc 96-week analysis of PULSAR.

Journal: Ophthalmology. Retina

Published: February 24, 2026

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Journal: Ophthalmology and therapy

Published: January 06, 2026

Prevalence of Polypoidal Choroidal Vasculopathy Beyond Recalcitrant Macular Neovasculopathies in a European AMD Cohort and Therapeutic Response to Brolucizumab.

Prevalence of Polypoidal Choroidal Vasculopathy Beyond Recalcitrant Macular Neovasculopathies in a European AMD Cohort and Therapeutic Response to Brolucizumab.

Journal: Journal of clinical medicine

Published: December 31, 2025

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Journal: Ophthalmology and therapy

Published: December 01, 2025

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report.

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report.

Journal: Ophthalmology science

Published: November 08, 2025

First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report.

First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report.

Journal: BMJ open ophthalmology

Published: September 01, 2025

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Journal: Ophthalmology and therapy

Published: August 11, 2025

Ocular Kinetics, Distribution, and Effects of Human VEGF Isoforms 121 and 165: Implications for Therapeutic Intervention.

Ocular Kinetics, Distribution, and Effects of Human VEGF Isoforms 121 and 165: Implications for Therapeutic Intervention.

Journal: Molecular pharmaceutics

Published: July 30, 2025

Showing 1-12 of 123

Last Updated: 09/26/2026